Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone …
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer: ASCO guideline rapid recommendation update
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib …
HJ Burstein, A DeMichele, L Fallowfield… - Journal of Clinical …, 2024 - ascopubs.org
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
[HTML][HTML] Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …
HJ Burstein, MR Somerfield, DL Barton… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human
Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline …
Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline …
Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated …
PURPOSE This guideline updates recommendations of the ASCO guideline on
chemotherapy and targeted therapy for patients with human epidermal growth factor …
chemotherapy and targeted therapy for patients with human epidermal growth factor …
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer …
HJ Burstein, A DeMichele, MR Somerfield… - Journal of Clinical …, 2023 - ascopubs.org
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO guideline update
SH Giordano, MAB Franzoi, S Temin… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …
[PDF][PDF] Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update
SH Giordano, S Temin… - J Clin …, 2018 - melbournebreastcancersurgery.com …
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive
Breast Cancer: ASCO Clinical Pra Page 1 JOURNAL OF CLINICAL ONCOLOGY ASCO …
Breast Cancer: ASCO Clinical Pra Page 1 JOURNAL OF CLINICAL ONCOLOGY ASCO …
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline
S Al Sukhun, S Temin, CH Barrios, NZ Antone… - JCO global …, 2024 - ascopubs.org
PURPOSE To guide clinicians and policymakers in three global resource-constrained
settings on treating patients with metastatic breast cancer (MBC) when Maximal setting …
settings on treating patients with metastatic breast cancer (MBC) when Maximal setting …
[HTML][HTML] Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American …
Purpose To identify optimal chemo-and targeted therapy for women with human epidermal
growth factor 2 (HER2)–negative (or unknown) advanced breast cancer. Methods A …
growth factor 2 (HER2)–negative (or unknown) advanced breast cancer. Methods A …
相关搜索
- asco guideline targeted therapy
- breast cancer targeted therapy
- hormone receptor targeted therapy
- growth factor targeted therapy
- practice guideline targeted therapy
- endocrine treatment targeted therapy
- american society targeted therapy
- asco guideline breast cancer
- targeted therapy for patients
- asco guideline hormone receptor
- asco guideline growth factor
- breast cancer growth factor
- breast cancer hormone receptor
- growth factor hormone receptor
- asco guideline update
- asco guideline esr1 mutations